gefitinib has been researched along with biochanin a in 1 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (biochanin a) | Trials (biochanin a) | Recent Studies (post-2010) (biochanin a) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 427 | 6 | 224 |
Protein | Taxonomy | gefitinib (IC50) | biochanin a (IC50) |
---|---|---|---|
Lysine-specific histone demethylase 1A | Homo sapiens (human) | 2.95 | |
Aromatase | Homo sapiens (human) | 0.0102 | |
Amine oxidase [flavin-containing] A | Homo sapiens (human) | 0.4 | |
Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.4 | |
17-beta-hydroxysteroid dehydrogenase type 2 | Homo sapiens (human) | 9.9 | |
Beta-hydroxyacyl-ACP dehydratase precursor (Fatty acid synthesis protein) | Plasmodium falciparum (malaria parasite P. falciparum) | 8 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
1 other study(ies) available for gefitinib and biochanin a
Article | Year |
---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |